|
From the recent issue of Breakthrough:
A Clinical Study for Osteogenesis Imperfecta in Adults
We are happy to report that both the Anaheim, CA and the Tacoma, WA sites for this trial of a new bone building drug have completed the recruit phase for the current study. They have reached the required number of participants needed at this time. These studies, sponsored by the pharmaceutical company Novartis are investigating a drug that blocks the body’s production of sclerostin and may lead to an increase in bone mass. If you would like to learn more about this study or if you might be interested in the next phase please visit the study websitehttp://www.comprehensivecd.com/osteogenesis-imperfecta-itn-11162/. Thank you to everyone who responded to the initial request for participants in this clinical trial.
Cardiopulmonary dysfunction in the OsteogenesisImperfecta Mouse Model Aga2 and human patients are causedby bone-independent mechanisms.
Rare Bone Disease Research Summit
Current Studies
A list of research studies that are currently recruiting participants
Participating in a Study
A guide to understanding the medical research study process
Research Update
Descriptions of research funded by the OI Foundation, summaries of scientific meetings and reports about research findings
OI Registry
A secure, electronic database that collects information about OI and matches members with research study opportunities
Apply for Grants for Medical Researchers
Information about Michael Geisman Research Fellowships, Seed Grants and Clinical Seed Grants, the OI Foundation Grant process and a link to the grant application.
|
